Abstract
We report the results of the evaluation of a series of imidazole-based compounds against the enzyme 17α- hydroxylase/17,20-lyase (P-45017α). The results show that the compounds were, in general, weak inhibitors of P-45017α in comparison to the standard inhibitor ketoconazole (KTZ) - one was, however, found to be more potent than KTZ.
Keywords: Androgen, Enzyme inhibitor, 17α-hydroxylase, Imidazole, 17,20-lyase, Prostate cancer, Biochemical, 2-imidazol-1-yl-1-phenyl-ethanone, P-45017α, cytochrome, androstenedione (AD), dehydroepiandrosterone (DHEA), progesterone, pregnenolone, NADPH, iron-monooxygen
Letters in Drug Design & Discovery
Title: Synthesis, Biochemical Evaluation and Rationalisation of the Inhibitory Activity of a Range of Derivatives of 2-imidazol-1-yl-1-phenyl-ethanone as Potential Novel Inhibitors of 17α-hydroxylase/17,20-lyase (P-45017α)
Volume: 8 Issue: 6
Author(s): Kruti Shah, Baljeet Jandu, Ammara Abdullah and Sabbir Ahmed
Affiliation:
Keywords: Androgen, Enzyme inhibitor, 17α-hydroxylase, Imidazole, 17,20-lyase, Prostate cancer, Biochemical, 2-imidazol-1-yl-1-phenyl-ethanone, P-45017α, cytochrome, androstenedione (AD), dehydroepiandrosterone (DHEA), progesterone, pregnenolone, NADPH, iron-monooxygen
Abstract: We report the results of the evaluation of a series of imidazole-based compounds against the enzyme 17α- hydroxylase/17,20-lyase (P-45017α). The results show that the compounds were, in general, weak inhibitors of P-45017α in comparison to the standard inhibitor ketoconazole (KTZ) - one was, however, found to be more potent than KTZ.
Export Options
About this article
Cite this article as:
Shah Kruti, Jandu Baljeet, Abdullah Ammara and Ahmed Sabbir, Synthesis, Biochemical Evaluation and Rationalisation of the Inhibitory Activity of a Range of Derivatives of 2-imidazol-1-yl-1-phenyl-ethanone as Potential Novel Inhibitors of 17α-hydroxylase/17,20-lyase (P-45017α), Letters in Drug Design & Discovery 2011; 8 (6) . https://dx.doi.org/10.2174/157018011795906749
DOI https://dx.doi.org/10.2174/157018011795906749 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Ubiquitin-Proteasome Pathway and Resistance Mechanisms Developed Against the Proteasomal Inhibitors in Cancer Cells
Current Drug Targets Prolactin and Blood-Brain Barrier Permeability
Current Neurovascular Research Vitamin D3 and Vitamin D3 Analogues as an Adjunct to Cancer Chemotherapy and Radiotherapy
Current Medicinal Chemistry - Anti-Cancer Agents Gas1 is a Pleiotropic Regulator of Cellular Functions: from Embryonic Development to Molecular Actions in Cancer Gene Therapy
Mini-Reviews in Medicinal Chemistry Some Recent Synthetic Development on Compounds with Potent Activities on Hormone-sensitive Breast Cancers
Current Organic Chemistry Occurrence and Biological Activities of Eremophilane-type Sesquiterpenes
Mini-Reviews in Medicinal Chemistry C-Abl Inhibition; A Novel Therapeutic Target for Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Ischemic and Oxidative Damage to the Hypothalamus May Be Responsible for Heat Stroke
Current Neuropharmacology Design of Lipophilic Prodrugs to Improve Drug Delivery and Efficacy
Current Drug Targets Bioactive Proteins and Peptides from Food Sources. Applications of Bioprocesses used in Isolation and Recovery
Current Pharmaceutical Design Curcumin as an Anti-Cancer Agent: Review of the Gap Between Basic and Clinical Applications
Current Medicinal Chemistry Daidzein and its Effects on Brain
Current Medicinal Chemistry Erythropoietin Withdrawal Leads to the Destruction of Young Red Cells at the Endothelial-Macrophage Interface
Current Pharmaceutical Design Editorial (Thematic Issue: Novel Therapeutic Strategies for Castration-resistant Prostate Cancer: Update and Future Perspectives)
Clinical Cancer Drugs Glutathione Peroxidase: A Potential Marker for the Most Common Diseases and Disorders
Recent Patents on Biomarkers Current Issues on Epileptic Women
Current Pharmaceutical Design FOXO and FOXM1 in Cancer: The FOXO-FOXM1 Axis Shapes the Outcome of Cancer Chemotherapy
Current Drug Targets Evolution and Structure of API5 and Its Roles in Anti-Apoptosis
Protein & Peptide Letters IO Nation: The Rise of Immuno-Oncology
Current Pharmacogenomics and Personalized Medicine Oncogenic Signalling Networks and Polypharmacology as Paradigms to Cope with Cancer Heterogeneity
Current Proteomics